Latest:
Dr. Laramore on Genetic Testing in Hematologic Cancers
Andrew Laramore, MD, Anatomic and Clinical Pathology, Diagnostic Pathology Services, discusses some of the known genes that are tested for in hematologic malignancies.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Andrew Loblaw, MD, FRCPC, MSc
Latest:
Dr. Loblaw on Monitoring Men With Intermediate-Risk Prostate Cancer
Andrew Loblaw, MD, FRCPC, MSc, clinician scientist, radiation oncologist, Sunnybrook Health Sciences Centre, discusses a study that looked at using active surveillance to monitor men with intermediate-risk prostate cancer.
Andrew Pecora, MD, FACP, CPE
Latest:
Dr. Pecora on Updated MAIA Data in Multiple Myeloma
Andrew Pecora, MD, FACP, CPE, president physician enterprise, chief innovation officer, John Theurer Cancer Center, Hackensack Meridian Health, discusses the impact age has on the efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (DRd) in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) as part of the MAIA study.
Andrew R. Branagan, MD
Latest:
Dr. Branagan on Vaccine to Better Protect Myeloma Patients From Flu
Andrew R. Branagan, MD, postdoctoral associate in Medicine (Hematology), Yale Cancer Center, discusses the significance of a vaccine developed to better protect patients with multiple myeloma from getting the flu.
Andrew S. Poklepovic, MD
Latest:
VCU Explores Novel Combos for Solid Tumors
Studies conducted at VCU Massey Cancer Center
in Richmond, Virginia, over the past 7 years
have developed the therapeutic combination of
pemetrexed and sorafenib (Nexavar) from
the bench to the bedside, and now into phase II clinical
trial evaluation.
Andrew Stephenson, MD
Latest:
Dr. Stephenson on Patient Preferences on Undergoing Active Surveillance for Prostate Cancer
Andrew Stephenson, MD, director of Urologic Oncology, Cleveland Clinic, discusses patient preferences with undergoing active surveillance versus active treatment for their prostate cancer.
Andrew Vassil, MD
Latest:
Hypofractionated and Stereotactic Body Radiotherapy in Prostate Cancer
Despite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.